EMA Mid-Year Report 2026: Reform, Supply and the First Joint Clinical Assessment
November 4, 2026
The EMA mid-year report 2026 (reference EMA/206392/2026, dated 29 October 2026) shows how the European Medicines Agency is delivering on its expanding remit. It covers the first half of 2026 and tracks progress in the main focus areas of the Single Programming Document (SPD) 2026-2028.
Legislation and supply: the new pharmaceutical law and the Critical Medicines Act
The provisional political agreement on the new pharmaceutical legislation (NPL) was reached on 11 December 2025 by the European Commission, the European Parliament and the Council. The report describes it as the most important overhaul of the regulatory framework in over two decades, changing how medicines are developed, authorised and made available to patients across the EU.
Let Google know we are your trusted source.
Add our editorial as a preferred source in your search results.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.